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Abstract 
Objective: The genetically modified mouse is the most commonly used animal model 
for studying the pathogenesis of atherosclerotic disease. We aimed to assess if mice 
atherosclerosis related genes could be validated in human disease through 
examination of results from genome wide association studies.  
Approach and Results: We performed a systematic review to identify 
atherosclerosis-causing genes in mice and carried out gene-based association tests 
of their human orthologues for an association with human coronary artery disease 
(CAD) and human large artery ischemic stroke (LAS). Moreover, we investigated the 
association of these genes with human atherosclerotic plaque characteristics. 
Additionally, we assessed the presence of tissue-specific cis-acting expression 
quantitative trait loci (eQTLs) for these genes in humans. Lastly, using pathway 
analyses we show that the putative atherosclerosis-causing genes revealed few 
associations with human CAD, LAS or atherosclerotic plaque characteristics, despite 
the fact that the majority of these genes have cis-acting eQTLs. 
Conclusions: A role for genes that has been observed in mice for atherosclerotic 
lesion development could scarcely be confirmed by studying associations of disease 
development with common human genetic variants. The value of murine 
atherosclerotic models for selection of therapeutic targets in human disease remains 
unclear.  
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Introduction 
Atherosclerosis is a multifactorial process that develops over decades, underlying 
the majority of cardiovascular diseases. Due to its slow progression, studying the 
natural history of atherosclerosis requires serial examinations, thus complicating the 
design of studies in humans. Most research on biological mechanisms of 
atherosclerosis has been performed in genetically modified mice, eliminating these 
challenges faced in human studies. Thus genetically modified mice elegantly allow 
the study of atherosclerosis in, arguably, the best-controlled model system possible. 
The most commonly used atherosclerotic murine models are Apolipoprotein E 
(ApoE) or Low-Density Lipoprotein Receptor (LDLR) gene knockouts. These mice 
clearly display an accelerated atherosclerotic phenotype with human-like vascular 
lesions1,2. Experimental modifications of these murine models may accelerate 
vascular plaque development resulting in advanced lesions within several weeks3,4. 
Consequently such models have been crucial in understanding the murine molecular 
and cellular basis of atherosclerosis. Yet, the relevance in human atherosclerotic 
disease remains elusive for a number of reasons. Primarily, the morphology of 
atherosclerotic plaque in mice differs from that of humans and acute events due to 
luminal thrombosis and evident plaque rupture are rarely observed. Secondly, 
clinical disease manifestations such as coronary artery disease (CAD) or ischemic 
stroke in mice are rare or lacking. Thirdly, it is arguable whether complete knockouts 
in mice correspond with expression-changing mutations in humans. Lastly, despite 
the knockout of individual genes, genetic redundancy on the pathway level further 
complicates the interpretation of results from animal models5.  
In recent years, millions of common single-nucleotide polymorphisms (SNPs) in the 
human genome were identified, and our understanding of these variants with respect 
to the genomic architecture has increased significantly6. This has opened up the 
possibility to agnostically assess the effects of genome-wide variation on human 
traits and disease7. Indeed, meta-analyses of human genome-wide association 
studies (GWAS) have identified many risk loci for CAD8 and large artery ischemic 
stroke (LAS)9. These GWAS provide the unique opportunity to validate the putative 
disease-causing genes identified through murine models in humans.  
We performed a systematic review to identify atherosclerosis-causing genes in mice 
and carried out gene-based association tests of their human orthologues for CAD 
and LAS. Moreover, we investigated the association of these genes with human 
atherosclerotic plaque characteristics. Furthermore, we assessed whether there are 
tissue-specific cis-acting expression quantitative trait loci (eQTLs) for the genes in 
humans. We report that putative atherosclerosis-causing genes reveal little 
association with human CAD, LAS or atherosclerotic plaque characteristics, despite 
the fact that the majority of these genes have cis-acting eQTLs. 
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Materials and Methods  
Materials and Methods are available in the online-only Data Supplement. 
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Results 
Of the 659 murine genes (table SI) a total of 486 genes (73.75%) were studied in 
knockout mice, 57 genes (8.65%) were studied in transgenic mice, and 116 genes 
(17.60%) were targeted by specific compounds (table SI). For 185 genes (28.07%) 
there are (pre-clinical) drugs available (table SI). 
 
Validation within GWAS of CAD and LAS 
We obtained summary statistics from GWAS on CAD8 and large artery stroke9 for 
SNPs ±50kb from the 5’ and 3’ gene borders of the 659 studied murine genes 
(Supplemental Material). We used these as input for a gene-based analysis using 
VEGAS which assigned an empirical p-value (after permutations) to each of the 659 
genes based on the p-value of the SNPs in and ±50 kb around the genes of 
interest10. Thus, each gene was given a p-value of association to CAD or LAS based 
on the GWAS results while taking into account the correlation between SNPs that 
may exist. Out of the 659 studied genes that have been shown to affect 
atherosclerotic phenotypes in mice, 11 (1.7%) genes were associated with CAD after 
correction for multiple testing (p-value ≤ 0.05/659 ≤ 7.59x10-5, table SIII). In contrast, 
none of the genes were associated with LAS after correction for multiple testing. The 
top 10 most significant genes for CAD and LAS are shown in table 1. A total of 84 
(12.7%) and 41 (6.2%) of the genes were associated with CAD and LAS 
respectively, at a nominal p-value ≤ 0.05. The overlap of associated genes between 
LAS and CAD is limited; only the locus at 9p21 (containing CDKN2A/B), significantly 
associated with CAD, was also nominally associated with LAS (p-value < 0.0062). 
We did not observe any further overlap between CAD and LAS top-associated 
genes. When looking at model groups to which the genes were assigned (knockout, 
transgenic or compound), we did not observe significant differences between groups 
for the 11 significant genes (p-value = 0.513 using a Chi2 test).  
 
Validation using human atherosclerotic plaque 
Subsequently, we conducted a similar gene-based analyses using VEGAS on seven 
plaque characteristics in the Athero-Express Biobank Study11. These human plaque 
characteristics have previously been associated with clinical presentation12 and have 
been examined in many atherosclerotic murine models. Overall, out of the 657 
genes a low number of genes nominally associated with a human plaque 
characteristic and followed the expectation under the null (range 4.1%-6.1%, table 
SV). Only two genes were significantly associated with human intraplaque 
macrophages, F10 on chromosome 13 (p-value = 1.00x10-6), and TNFAIP8L2 on 
chromosome 1 (p-value = 5.80x10-5) after correction of multiple testing. All gene-
based association results for the 659 target genes with plaque characteristics are 
provided in table SVI.  
 
Validation using pathway analyses 
The genes that reached nominal significance in the gene-based analysis of CAD and 
LAS, were further analyzed using Ingenuity to identify canonical pathways 
associated with CAD and LAS (table SIV). Table 2 provides the 25 most significant 
canonical pathways based on the 659 murine target genes and the translation of 
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these genes to human CAD and LAS. The LXR/RXR activation pathway (involved in 
lipid metabolism) that has been extensively studied in atherosclerotic mice, was 
found to be significantly enriched for genes associated with CAD and LAS. In 
contrast, the NFκB inflammatory signaling pathway that has been extensively studied 
in murine models, revealed less genes that associated with CAD or LAS (table 2). 
Another example is the T-lymphocyte differentiation pathway that has been 
extensively studied in mice and associated with murine atherosclerosis, but for which 
we found little supportive evidence in our gene-based analysis associating with 
human CAD or LAS.  
 
eQTL analysis of the murine genes 
In murine models the 659 genes are clearly affected through knockout, transgenic 
techniques or targeted compound treatment. A close human analogue of such an 
effect would be cis-acting common genetic variants affecting gene expression 
through reducing or upregulating expression. Such variants are known as expression 
quantitative trait loci (eQTLs). We conducted cis-eQTL analyses using the STAGE 
study and queried three online public resources (table SVII) to identify common 
variants modulating the expression of the 659 genes in humans. Across the four 
datasets and 11 cell/tissue types we found eQTLs (p-value ≤ 7.31x10-7 after 
correction for 68,402 variants in and around these genes) for 411 out of the 659 
genes (these genes are marked orange in table SVIII). For all genes we found SNPs 
in cis affecting expression (p-value < 0.05) in any of the four datasets queried (table 
SVIII). In a representative example of a canonical pathway (NFκB) we show that 
each target gene has a cis-eQTL, i.e. a common variant (SNP) in or around the gene 
that has a significant effect on tissue-specific gene expression in humans. 
Not all genes will exert their effect on clinical outcome via gene expression, rather 
gene function. Thus, we compared the gene-based association results for CAD and 
LAS for the genes with a valid eQTL (p-valueeQTL < 7.31x10-7) and without (p-
valueeQTL ≥ 7.31x10-7), but found no significant difference in enrichment for disease 
association in either CAD (p-value = 0.882) or LAS (p-value = 0.634). Similarly, we 
compared the gene-based association results between the model groups for the 84 
and 42 genes that associated with CAD and LAS (knockout, transgenic, or 
compounds) and found a statistical difference between groups for CAD (p-value = 
0.0013, Chi2 = 13.291). A pairwise comparison of the three model groups revealed 
that knockout and compounds do not have statistically different gene-based results 
(p-value = 0.718), whereas the results between knockouts and transgenic mice (p-
value = 0.00049, Chi2 = 12.146) or transgenic mice and compounds do (p-value = 
0.0029, Chi2 = 8.852). We found no statistical difference for LAS (p-value = 0.637) 
when comparing the three model groups. We also stratified our pathway analyses 
based on these three model groups, but this revealed no additional significant 
pathways. 
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Discussion 
This study shows that putative atherosclerosis-causing genes identified in murine 
atherosclerosis models, reveal little association with human CAD, LAS or 
atherosclerotic plaque characteristics, despite the fact that the majority of these 
genes have cis-acting eQTLs.  
Overall, the majority of genes associated with an atherosclerotic phenotype in mice 
do not carry variants that associate with human CAD, LAS or advanced plaque 
characteristics. In contrast, murine genes involved in lipid metabolism significantly 
associated with human CAD which is consistent with the known role of lipids in CVD 
risk. Indeed, lipid-lowering drugs, such as statins, act through HMGCR (chromosome 
5q13.3) to lower circulating lipids13. A recent GWAS showing that variants in the 
HMGCR locus are associated with an increase of 2.84 mg/dL total cholesterol14, 
effectively confirmed this drug action retrospectively. However, for most murine 
genes and pathways of innate and adaptive immunity, there was no association with 
human CAD, LAS or plaque characteristics.  
ApoE-/- and LDLR-/- models are widely used to study the initiation and progression of 
atherosclerosis. To study the effect on plaque development15 or therapeutic 
strategies16, additional (double) knockout or transgenic atherosclerotic models have 
been developed. Yet, they lack plaque rupture thrombosis and subsequent cardiac 
or cerebral ischemia. Although therapeutic strategies have been developed based on 
animal models, failures in clinical utilization underscores the need for human 
verification and translation before initiating targeted drug development programs17,18. 
Indeed, a post hoc analysis by deCODE genetics and Amgen assessed the validity 
of results from human genetic studies as positive predictors of successful clinical 
trials19. Essentially all failed clinical trials targeting a gene (locus) lack any evidence 
from genetic association studies19. 
 
There are several potential explanations for the observed discrepancies of genes 
involved in atherosclerotic murine studies and human cardiovascular disease. First, 
they may be explained by differences in effect sizes. Common genetic variants 
associated with human disease often have a modest effect, in contrast to 
experimental gene manipulation (i.e. knockout) in animal models to study 
atherosclerotic disease. These genetic modifications in mice limit inferences 
regarding dose dependent effects which is relevant for predicting drug effects in 
human disease. Furthermore, the combined effect of human population history and 
selection may have yielded very little functional genetic variation and thus no 
association with CAD or LAS, even in a large sample. The low number of murine 
genes associated with plaque characteristics in the Athero-Express study may be 
explained by limited sample size and therefore should be interpreted with caution.  
However, for our gene-based analysis of CAD and LAS, we had access to GWAS 
results based on large mete-analyses, providing substantial statistical power to 
detect genes associated with disease. In addition, we studied the enrichment of 
murine derived atherosclerosis-related gene sets within canonical pathways. We 
then tested whether their human orthologues (that were nominally associated with 
disease based on a gene-based test) were also observed in these pathways. For the 
majority of pathways, weak or even absent evidence was found in humans. Of note 
is the LXR pathway which is proven to be linked with human cardiovascular disease, 
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and for which we found ample evidence using our gene-based and our pathway 
analysis. Furthermore, in atherosclerotic mouse models, plasma lipid levels are the 
main determinant of lesion development. The associations between mice and human 
GWAS studies may improve when human individuals are studied with (genetic) 
susceptibility to abnormal lipid metabolism. Such interactions have not been 
explored in the present study. However, such an association would imply that the 
atherosclerotic mouse models cannot represent disease development in the general 
population. 
Second, one might argue that the SNP to gene mapping done by VEGAS is over-
conservative and consequently excludes (regulatory) variants of greater effect that 
may lie as far as 1Mb. However, most variants significantly affecting gene 
expression are found within 50 kb of the gene body20, and regulatory elements are 
usually found in intergenic regions. Nevertheless, it is unlikely that erroneous 
annotations alone can explain the strong discrepancy between murine genes and 
their human orthologues within pathways.  
Third, undoubtedly the Ingenuity Knowledge Base is a comprehensive summary of 
the current knowledge from literature on gene networks and pathways. While it is 
constantly updated and manually curated, our Ingenuity based pathway analysis is 
biased. Indeed, genes (and thereby networks and pathways) that are not studied (in 
humans or any model system) would simply not exist in Ingenuity, thus partly 
explaining an apparent discrepancy between associated pathways in humans and 
mice. In addition, pathways are often cell and organ specific and a selective 
approach towards cell types that are considered to play a dominant role in 
atherogenesis may affect the readout of our pathway analyses. 
Fourth, the annotation of candidate genes to GWAS loci is usually based on 
literature and proximity to the genome-wide significant SNP, but whether such a 
gene actually influences disease is still unknown. For our gene-based approach we 
mapped the mouse genes to their human orthologue and tested their association 
with CAD or LAS. Therefore, the genes that have been annotated to GWAS loci may 
not appear in our results even when the SNPs in their proximity meet the genome-
wide significance threshold. 
Lastly, a transgenic or compound-treated mouse may not be comparable to a 
knockout model, thus explaining the lack of association of these genes with human 
disease. Given the statistically different gene-based results, we stratified our 
pathway analyses based on these three different model types, and found no 
difference. Hence, it is unlikely that the type of murine intervention model explains 
the lack of association with human disease. 
 
Previous studies have raised doubts upon the validity of translating murine models to 
human pathophysiology in studying immune responses21-23 although conflicting 
results have been obtained24. Our study adds to the debate on the relevance of 
murine models for human atherosclerotic disease, and supports the view that the 
direction of the scientific process matters. The lack of association of murine 
atherosclerotic genes with human CAD, LAS or human plaque characteristics may 
be due to diverged gene expression patterns among mice and humans resulting in 
different phenotypic effects. Indeed, results from the recently published Mouse 
ENCODE project show that gene expression patterns diverge between mice and 
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humans25,26. Moreover, phenotypic effects of orthologous genes frequently differ 
between species. This suggests that a sensible approach would be to group genes 
based on mouse-human orthology in order to improve the translational power of 
putative murine genes. Genome-wide association studies agnostically provide 
human evidence for the involvement of genetic loci in the underlying mechanisms of 
atherosclerotic disease, including CAD and LAS. Therefore, from the outset, the 
rationale to initiate an examination of the role of genes in these loci in murine models 
of atherosclerosis could be supported by human data. 
Our study may have several limitations. Individuals of non-European descent are 
underrepresented in the GWAS we examined. It remains to be investigated if results 
will differ for GWAS in non-European cohorts. 
The genetic association study on human plaque characteristics was executed in the 
Athero-Express study and included 1,443 patients with significant atherosclerosis. 
Although this study represents the largest collection of histologically investigated 
plaques, this study may suffer from limited power when examining the genetics of 
plaque characteristics.  
We studied all published papers that applied the ApoE-/- and LDLR-/- as a model for 
atherosclerosis. However, alternative murine models have been studied in 
atherosclerotic disease that we did not include in our search and we cannot exclude 
that these reveal better associations with the human genetic outcome studies.  
In conclusion, a role for genes that has been observed in mice for atherosclerotic 
lesion development could scarcely be confirmed studying associations of disease 
development with common human genetic variants indicating that knockout models 
of atherosclerosis are not a good reflection of the variation that underlies common 
forms of atherosclerosis. The value of murine atherosclerotic models for selection of 
therapeutic targets in human disease remains unclear. 
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Significance 
While many putatively atherosclerosis-causing genes have been identified through 
the genetically modified mouse model, the translation to human atherosclerotic 
disease has been notoriously challenging. Here we systematically reviewed literature 
to identify putative atherosclerosis-causing genes in mice. We identified their human 
orthologs and performed gene-based association tests on human coronary artery 
disease, ischemic stroke and plaque characteristics. Of the 659 identified genes, 11 
were associated with CAD, none with stroke, and 2 with intraplaque macrophages. 
Pathway analyses confirmed the limited association with human disease, despite the 
fact that many genes have a cis-eQTL. Our study underlines the need for human 
validation of murine atherosclerosis-causing genes. 
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.        CARDIoGRAM METASTROKE 
Gene Chr start end 
n 
SNPs P FDR best SNP 
P best 
SNP n SNPs P FDR best SNP P best SNP 
CDKN2A 9 21.957.750 21.984.490 100 
<2.00x10-
6 
<2.00x10-
6 rs10738604 
2.27x10-
16 120 0,006 0,380 rs634537 1.05x10-4 
CDKN2B 9 21.992.901 21.999.312 92 
<2.00x10-
6 
<2.00x10-
6 rs10738604 
2.27x10-
16 107 0,003 0,349 rs634537 1.05x10-4 
MRAS 3 139.549.314 139.607.067 81 
<2.00x10-
6 
<2.00x10-
6 rs2306374 3.34x10-8 93 0,637 0,911 rs10513053 0,026 
APOA5 11 116.165.295 116.167.794 77 2.00x10-6 3.29x10-4 rs964184 
8.02x10-
10 114 0,533 0,891 rs5110 9.21x10-3 
LPL 8 19.840.861 19.869.050 177 5.00x10-6 6.57x10-4 rs3779788 2.40x10-7 199 0,079 0,753 rs2410616 4.34x10-3 
TGFB1 19 46.528.490 46.551.656 54 7.00x10-6 7.67x10-4 rs12327659 3.93x10-6 77 0,095 0,753 rs2217656 8.39x10-4 
LDLR 19 11.061.056 11.105.505 101 9.00x10-6 8.45x10-4 rs1122608 
9.73x10-
10 119 0,044 0,749 rs1799898 3.14x10-3 
LIPA 10 90.963.305 91.001.640 154 1.30x10-5 1.07x10-3 rs7922269 7.56x10-6 174 0,079 0,753 rs4933497 5.03x10-3 
GIP 17 44.390.916 44.400.954 59 1.50x10-5 1.10x10-3 rs46522 3.57x10-6 69 0,121 0,794 rs4794015 0,020 
APOA4 11 116.196.627 116.199.221 65 1.70x10-5 1.12x10-3 rs964184 
8.02x10-
10 101 0,353 0,891 rs5110 9.21x10-3 
IL25 14 22.911.857 22.915.452 88 0,046 0,370 rs10143597 2.75x10-3 116 0,001 0,171 rs12894524 4.52x10-5 
MMP12 11 102.238.673 102.250.922 114 0,055 0,408 rs7124926 4.25x10-3 132 0,001 0,171 rs660599 4.74x10-5 
MMP3 11 102.211.737 102.219.552 135 0,079 0,454 rs2408489 5.72x10-3 158 0,001 0,171 rs475007 4.05x10-5 
MAPK7 17 19.221.658 19.227.445 27 0,119 0,509 rs739830 1.53x10-3 46 0,006 0,380 rs1110467 1.27x10-4 
MMP9 20 44.070.953 44.078.607 82 0,126 0,509 rs7270354 1.94x10-4 95 0,005 0,380 rs17448653 1.06x10-4 
ALOX15B 17 7.883.082 7.893.176 90 0,202 0,635 rs4792214 6.92x10-3 111 0,006 0,380 rs4792203 9.36x10-5 
CD40 20 44.180.312 44.191.791 123 0,253 0,689 rs1321003 8.17x10-3 142 0,000 0,091 rs4239702 1.41x10-5 
TGFB3 14 75.494.194 75.517.845 67 0,902 0,965 rs8008060 0,090 82 0,000 0,120 rs3917187 4.16x10-5 
 
Table 1: Top 10 gene-based association results of the 659 target genes for CAD and LAS. CARDIoGRAM: meta-analysis of GWAS of 
CAD. METASTROKE: meta-analysis of GWAS of LAS. Results are given per gene with its chromosomal (chr) start and end base pair 
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.position. n SNPs: number of SNPs studied for that gene. Also given are the most significant (best) SNP for that gene and its p-value. 
P-values are in bold for genes with Bonferroni corrected p-valuegene ≤ 7.59x10-5, and italic for genes with nominal p-value < 0.05. 
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Rank Ingenuity canonical pathways Overlap pathways 
CARDIoGRAM METASTROKE Murine genes 
N genes p ≤ 0.05 P N genes p ≤ 0.05 P 
N genes  
p ≤ 0.05 
N genes  
p > 0.05 
1 LXR/RXR Activation 59/121 (49%) 16 1,84E-08 5 0,098 19 40 
2 FXR/RXR Activation 50/125 (40%) 12 4,22E-06 1 0,202 13 37 
3 PPARα/RXRα Activation 40/165 (24%) 10 1,78E-05 2 0,278 12 28 
4 Clathrin-mediated Endocytosis Signaling 27/184 (15%) 8 3,27E-05 4 0,034 10 17 
5 Acute Phase Response Signaling 53/168 (32%) 11 4,32E-05 2 0,252 13 40 
6 Glioma Invasiveness Signaling 11/57 (19%) 5 1,06E-04 1 0,329 6 5 
7 Atherosclerosis Signaling 58/120 (48%) 11 1,17E-04 8 
6,33E-
03 17 42 
8 Oncostatin M Signaling 13/34 (38%) 5 2,67E-04 3 0,021 7 6 
9 IL-12 Signaling and Production in Macrophages 47/131 (36%) 9 3,79E-04 4 0,123 12 35 
10 TR/RXR Activation 21/85 (25%) 6 3,93E-04 1 0,376 6 15 
11 Hepatic Fibrosis / Hepatic Stellate Cell Activation 70/196 (36%) 11 5,12E-04 6 0,077 15 55 
12 Adipogenesis pathway 22/124 (18%) 6 5,13E-04 2 0,207 7 15 
13 Cellular Effects of Sildenafil (Viagra) 9/124 (7%) 4 6,09E-04 0 0,630 4 5 
14 VEGF Signaling 23/89 (26%) 6 6,59E-04 0 0,307 6 17 
15 Hepatic Cholestasis 51/158 (32%) 9 6,89E-04 3 0,222 11 40 
16 Production of Nitric Oxide and Reactive Oxygen Species in Macrophages 42/179 (23%) 8 8,06E-04 3 0,194 10 32 
17 p70S6K Signaling 18/118 (15%) 5 1,37E-03 1 0,376 6 12 
18 Relaxin Signaling 19/132 (14%) 5 1,77E-03 1 0,377 6 13 
19 LPS/IL-1 Mediated Inhibition of RXR Function 38/208 (18%) 7 2,01E-03 2 0,277 9 29 
20 Glioma Signaling 20/94 (21%) 5 2,24E-03 2 0,189 5 15 
21 Nitric Oxide Signaling in the Cardiovascular System 20/95 (21%) 5 2,24E-03 1 0,377 6 14 
22 Endothelin-1 Signaling 30/167 (18%) 6 2,71E-03 3 0,127 8 22 
23 VEGF Family Ligand-Receptor Interactions 21/76 (28%) 5 2,80E-03 0 0,341 5 16 
24 eNOS Signaling 21/135 (16%) 5 2,80E-03 1 0,376 6 15 
25 Renal Cell Carcinoma Signaling 13/69 (19%) 4 2,82E-03 0 0,513 4 9 
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.Table 2: Top-25 canonical pathways for murine target genes. For each Ingenuity canonical pathway, the number and percentage of 
murine genes overlapping with the total number of pathways was determined (Overlap). For coronary artery disease (CARDIoGRAM) 
and large artery stroke (METASTROKE) the number of murine genes reaching p ≤ 0.05 (N genes p ≤ 0.05) for association with the 
respective disease is given. P indicates the binomial p-value and represents the proportion of murine genes associated with the 
disease compare to the total number of murine genes. For all murine genes the total N genes p ≤ 0.05 and N genes p > 0.05 for 
association with either disease is given. 
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Materials and methods  
Literature search 
A systematic search was performed at PubMed MEDLINE 
(http://www.ncbi.nlm.nih.gov) and Embase (http://www.embase.com) until July 
1st 2014 using the key words (or synonyms and thereof): “ApoE-/-”, “LDLR-/-, 
“atherosclerosis”, “plaque”, and “mice”. After removal of duplicates we 
identified 11,219 publications (fig. SI).  
Based on title and abstract, publications were manually selected that met the 
following criteria:  
- Murine knockout model on an atherosclerotic background (either ApoE-/- 
or LDLR-/-) that resulted in altered atherosclerotic plaque characteristics 
or altered plaque volume.  
- Murine transgenic model on atherosclerotic background that resulted in 
altered atherosclerotic plaque characteristics or altered plaque volume 
- Murine model on atherosclerotic background with a targeted 
intervention that resulted in altered plaque characteristics or plaque 
volume, either treated with a chemical compound or a biological entity 
(e.g. an antibody, hormone, siRNA or morpholino) that is recognized for 
protein or gene specificity. 
 
Gene selection for human extrapolation 
In total 2,076 papers met our predefined criteria (fig. SI) and we distilled 703 
unique murine genes (table SI). Subsequently these genes were mapped to 
their human orthologues using an automatic script together with the search 
function of GeneCards (http://genecards.org). Results were manually checked 
for accuracy. 
When a single murine gene mapped to multiple human orthologous genes, all 
human orthologues were included. We grouped each gene into one of three 
hierarchical categories (knockout, transgenic or compound) if any of the 
associated articles reported the gene in a knockout model, a transgenic 
model, or as a specific target of a chemical compound or biological entity 
(table SI). We excluded genes that could not be mapped by the gene-based 
association analysis software (n=21) or mapped to the X-chromosome genes 
(n=23). A total of 659 murine genes could be mapped to a human orthologue 
on genome build 36 and was thus available for downstream analyses (table 
SI). 
 
Athero-Express Biobank Study: plaque collection and phenotyping 
The details of the study-design and the plaque phenotyping have been 
described elsewhere1. In short, carotid plaque specimens were obtained from 
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carotid endarterectomy (CEA) patients during surgery. Plaques were 
immediately processed in the laboratory, where the culprit lesion with a length 
of 5 mm was fixed in 4% formaldehyde, subsequently followed by 
decalcification and embedding in paraffin. Cross-sections (5 µm) were sliced 
and routinely stained for different characteristics: atheroma size (based on 
interpretation of hematoxylin and eosin (HE), elastica von Gieson and 
collagen staining (picrosirius red)), macrophages (CD68), smooth muscle 
cells (α smooth muscle actin (SMA)), collagen, calcification (assessed using 
HE), intraplaque haemorrhage (HE and fibrin), and intraplaque vessel density 
(CD34)2. Collagen and calcified regions were semi-quantitatively scored as 
absent/minor vs. moderate/ heavy staining. Atheroma size was semi-
quantitatively analyzed as <40% vs. >40% intraplaque fat content. CD68 and 
SMA were visualized with DAB (3,3’-diaminobenzidine), and were 
quantitatively analyzed using AnalySIS 3.2 software (Soft Imaging Systems 
GmbH, Münster, Germany) and expressed as % of plaque area. Likewise 
CD34 was visualized using DAB and the number of vessels per 3-4 hotspots 
per plaque was determined. Intraplaque haemorrhage was semi-quantitatively 
scored as no vs. yes. 
 
Genome-wide association study summary statistics of CAD and LAS 
To test the association of genes with atherosclerotic disease, we obtained 
summary statistics from GWAS on the traits of interest as follows. Data for 
CAD were downloaded from the CARDIoGRAMplusC4D website 
(http://www.cardiogramplusc4d.org). These data are the results from 
CARDIoGRAM, a meta-analysis of 14 GWAS on CAD comprising of 22,233 
cases and 64,762 controls of European descent3. Data for LAS were obtained 
from METASTROKE4 (http://www.strokegenetics.com/members-area/meta-
stroke), a meta-analysis of data from 15 ischemic stroke cohorts with a total of 
12,389 cases and 62,004 controls, all of European ancestry. In 
METASTROKE 2,167 cases were determined to be of the “large artery stroke” 
subtype according to the TOAST classification system5, with matching 49,159 
controls. More details on genotyping, imputation, and study inclusion of the 
CARDIoGRAM and METASTROKE meta-analyses of GWAS can be found in 
the respective publications3,4. 
 
Athero-Express Biobank Study: genotyping 
The targeted SNP based analyses in-silico analyses were performed using 
data from two imputed genome-wide genotyping experiments carried out in 
1,858 consecutive patients from the AE. For these experiments DNA was 
extracted from blood or plaque samples (when no blood was available) 
following standardized in-house validated protocols. The first dataset (Athero-
Express Genomics Study 1, AEGS1) was genotyped using Affymetrix 
Genome-Wide Human SNP Array 5.0, the second dataset (Athero-Express 
Genomics Study 2, AEGS2) was genotyped using the Affymetrix Axiom® GW 
CEU 1 Array. We adhered to community standard quality control and 
assurance (QCA) procedures to clean the whole-genome data obtained in 
AEGS1 and AEGS26. We used the HapMap 2 CEU release encompassing 
over 2.5 million SNPs as the reference panel for imputation for autosomal 
missing genotypes in the 1,443 individuals that passed the QC. Depending on 
the phenotype we applied linear or logistic regression models adjusting for 
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age, sex, year of surgery, chip-type, and 10 principal components. We 
assumed an additive genetic model. 
We obtained summary level data from targeted SNP-based analyses (focused 
on SNPs in and around [±50kb] the 659 genes) on 7 plaque characteristics in 
the Athero-Express Biobank Study (AE). The local ethical committee 
approved the study and all patients gave written informed consent after the 
nature and possible consequences of the study were explained. 
 
eQTL of human orthologues of selected murine genes  
There is no human analogue for murine genetically modified models, other 
than naturally occurring genetic variation that affects gene expression (known 
as expression quantitative trait locus, eQTL). Therefore, we identified eQTLs 
through two approaches. First, we queried three online resources (table SVI) 
for eQTLs in lymphoblastoid cells7,8, monocytes9, subcutaneous adipose 
tissue7, and skin tissue7. Secondly, we performed eQTL analyses in 7 tissue 
types that could be relevant for disease development in the STAGE study10.  
 
The Stockholm Atherosclerosis Gene Expression (STAGE) Study 
In the STAGE study, seven vascular and metabolic tissues of well-
characterized coronary artery disease (CAD) patients were sampled during 
coronary artery bypass grafting (CABG) 10. The samples from atherosclerotic 
arterial wall (AAW), internal mammary artery (IMA), liver, skeletal muscle 
(SM), subcutaneous fat (SF), visceral fat (VF), and fasting whole blood (WB), 
were obtained during CABG for DNA and RNA isolation. Patients were 
included if they were eligible for CABG and had no other severe systemic 
diseases (e.g. widespread cancer or active systemic inflammatory disease). 
In order to prepare inferred genotypes for STAGE for genotype imputation, 
SNPs were quality controlled for minor allele frequency MAF < 5%, Hardy-
Weinberg equilibrium (HWE) p-value < 1x10-6, and call rate of 100%. 
Thereafter, genotypes for the STAGE study were imputed using IMPUTE2 
using 1000 Genomes EUR as the reference11. Quality control measures for 
imputed genotypes used an additional filter of IMPUTE2 INFO score of < 0.3. 
This yielded a total of 5,473,585 SNPs. The Ethical committee of the 
Karolinska Hospital approved the study, and all patients gave written informed 
consent after the nature and possible consequences of the study were 
explained. 
 
As previously described(9), an expression trait was tested for association with 
each genotyped and imputed SNP using Kruskal-Wallis test and false 
discovery rate to correct for multiple testing. First, all cis-pairs of SNPs within 
50kb of the transcription start or end site for each gene were identified. Next, 
cis SNP-gene pairs were tested for association in all seven STAGE tissues 
using kruX12. The p-value for eQTL inclusion in kruX was set at 0.05. Finally, 
an empirical FDR estimate for each eQTL-gene pair was calculated using ten 
permutations by shuffling patient IDs on genotype data. As a result, the most 
significant eQTL-gene association in each tissue was reported. 
 
Gene based association study of target genes 
We used “a versatile gene-based association study” (VEGAS)13 to calculate 
gene-based association statistics from the summary statistics of each target 
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gene for each trait. The details of the methods applied by VEGAS have been 
described elsewhere13. In short, SNPs are mapped to the gene (in and around 
±50kb from 5’ and 3’ gene borders), and using the GWAS p-value a gene-
based test statistic is calculated corrected for the underlying population 
linkage disequilibrium structure (based on HapMap 2 CEU). Finally using 
simulations an empirical gene-based p-value of association with the 
phenotype is calculated per gene13. 
 
Pathway analysis 
The 659 genes were analyzed through the use of QIAGEN’s Ingenuity 
Pathway Analysis (IPA, 2014 winter version, QIAGEN Redwood City, 
www.qiagen.com/ingenuity)14. We used IPA to identify canonical biological 
pathways within the Ingenuity Knowledge Base to which the murine gene 
targets were mapped. Only direct relationships that were experimentally 
observed in humans were included in the analysis. 
 
Statistical analyses 
This study focused on 659 human orthologous genes for the atherosclerotic 
murine genes and thus, in our gene-based analyses of the atherosclerotic 
disease traits (CAD, LAS, and the 7 plaque characteristics), we corrected 
conservatively for multiple testing (p-valuegene = 0.05/659 = 7.59x10-5). 
However, to allow optimal description of relevant biological pathways (in IPA) 
with the trait we also report data using a nominal p-value < 0.05. In the public 
eQTL sources there is no information on the number of SNPs mapped in and 
around ±50kb of the genes, we only were able to obtain the total number of 
eQTLs. STAGE uses 1000G imputed data and thus has denser SNP 
coverage per gene. In STAGE we mapped a total of 68,402 independent 
common SNPs in and around ±50kb of the genes for the cis-eQTL analysis. 
Therefore based on these numbers, we conservatively set the threshold at p-
valueeQTL = 0.05/68,402 = 7.31x10-7. We queried the 4 eQTL studies and 
noted the total number of nominally associated (p<0.05) eQTLs (within the 
±50kb range) with the target gene expression. We also report the most 
significantly associated eQTL for each gene. The three mouse model groups 
(knock-out, transgenic and compound) were compared using chi-square tests. 
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Figure SI. Flow-chart showing the filtering and selection of relevant 
papers and the identification of murine atherosclerotic genes mapped to 
human orthologues. A total of 11,219 papers were screened, and 2,076 met 
our predefined criteria. From those 2,076 papers we distilled 703 unique 
genes or compounds targeting genes on which we applied filters as described 
in the methods. Finally we mapped 659 murine genes to their human 
orthologue. VEGAS: a versatile gene-based association study software. 
GWAS: genome-wide association study.  
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Supplemental Tables  
Supplemental tables SI through SVII are available in a separate Excel-file. 
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